Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

273 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Sustained Improvements in Clinical and Patient-Reported Outcomes and Quality of Life Through 5 Years Among Ixekizumab-Treated Patients with Complete Clearance of Scalp Psoriasis by Week 60.
Egeberg A, Hawkes JE, Somani N, Burge R, See K, Gallo G, McKean-Matthews M, Gooderham M, Han G, Armstrong A. Egeberg A, et al. Among authors: see k. Dermatol Ther (Heidelb). 2024 Apr;14(4):1007-1018. doi: 10.1007/s13555-024-01147-7. Epub 2024 Apr 22. Dermatol Ther (Heidelb). 2024. PMID: 38647975 Free PMC article.
Dynamic Visual Representation of Clinical Efficacy of Ixekizumab in Psoriasis.
Hawkes JE, See K, Burge R, Strakbein S, McKean-Matthews M, Saure D, Gooderham M, Leonardi C. Hawkes JE, et al. Among authors: see k. Dermatol Ther (Heidelb). 2021 Aug;11(4):1107-1118. doi: 10.1007/s13555-021-00548-2. Epub 2021 May 29. Dermatol Ther (Heidelb). 2021. PMID: 34050899 Free PMC article. Review.
Effect of Ixekizumab on Patient Reported Outcomes and Quality of Life in Patients With Moderate-to-Severe Plaque Psoriasis: 5-Year Results from the UNCOVER-1 and -2 Studies.
Gooderham MJ, Elewski B, Augustin M, Iversen L, Torii H, Burge R, See K, Gallo G, Eastman WJ, McKean-Matthews M, Foley P. Gooderham MJ, et al. Among authors: see k. J Drugs Dermatol. 2021 Apr 1;20(4):394-401. doi: 10.36849/JDD.2021.5821. J Drugs Dermatol. 2021. PMID: 33852247 Clinical Trial.
Ixekizumab provides persistent improvements in health-related quality of life and the sexual impact associated with moderate-to-severe genital psoriasis in adult patients during a 52-week, randomised, placebo-controlled, phase 3 clinical trial.
Ryan C, Guenther L, Foley P, Weisman J, Burge RT, Gallo G, See K, McKean-Matthews M, Bertram CC, Merola JF. Ryan C, et al. Among authors: see k. J Eur Acad Dermatol Venereol. 2022 Apr;36(4):e277-e279. doi: 10.1111/jdv.17836. Epub 2021 Dec 4. J Eur Acad Dermatol Venereol. 2022. PMID: 34812561 Free PMC article. Clinical Trial. No abstract available.
273 results